Topic: Somaxon Pharmaceuticals Inc.
Somaxon Pharmaceuticals (SOMX) has finally delivered a deal on Silenor, and it is an unusual one. For a fixed fee and royalties, Somaxon has hired the OTC sales force of consumer products giant Procter & Gamble (PG) for a September launch of ...
Somaxon, Procter & Gamble agree to co-promote new insomnia drug SilenorSomaxon Pharmaceuticals Inc. will team with Procter & Gamble Co. to co-promote the insomnia treatment Silenor to thousands of doctors and pharmacies.The companies will combine sales forces to target 35,000 of the ...
Combined Sales Forces to Launch Silenor to Physicians in September Procter & Gamble to Provide Pharmacy Calls and Supplemental Managed Care Support Silenor OTC Negotiation Rights Included Conference Call Scheduled for Today at 9:00 a.m. Eastern Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced ...
Somaxon to sell 4 million shares to raise funds for marketing insomnia drug SilenorJust days after receiving Food and Drug Administration approval for Silenor, biotech company Somaxon Pharmaceuticals Inc. made plans to sell 4 million shares to fund marketing of the insomnia ...
Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.. Silenor is approved for the treatment of both ...
The FDA will complete its review and provide an action letter to Somaxon Pharmaceuticals (SOMX) relating to the Silenor NDA by December 4, 2009.. In the letter, the FDA denied approval for the insomnia drug Silenor in its present form since it ...
Four poster presentations highlight data from the clinical development program of Silenor? (doxepin) for the treatment of insomnia. SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment ...
SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that data from a pharmacological profiling study relating to doxepin, the ...
From Around the Web
Video Gallery
-
News Update: Somaxon Pharmaceuticals' Shares Surge...
"Shares of Somaxon Pharmaceuticals (NASDAQ:SOMX) are trading 31.2 ...2010-08-25 -
(TISI, KALU, SOMX) CRWENewswire Stocks to ...
Welcome to CRWENewswire, Stocks to watch for Tuesday October 4th ...2011-10-03 -
Chart of the Day - ASTC, NLST ...
02/24/10 - www.TheTechTrader.com - Astrotech Corp. (ASTC) was ...2010-02-25
